Press Releases Year None20222021202020192018201720162015201420132012 May 12, 2022 Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update May 5, 2022 Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022 May 3, 2022 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration April 26, 2022 Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022 April 25, 2022 Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness April 13, 2022 Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer April 11, 2022 Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022 March 24, 2022 Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022 March 21, 2022 Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss March 14, 2022 RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS March 10, 2022 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update March 1, 2022 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022 January 24, 2022 Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022 January 4, 2022 Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
May 12, 2022 Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
May 3, 2022 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
April 26, 2022 Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
April 25, 2022 Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
April 13, 2022 Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
March 24, 2022 Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
March 21, 2022 Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
March 14, 2022 RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
March 10, 2022 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 1, 2022 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 10, 2022
January 24, 2022 Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022
January 4, 2022 Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
